Mylan NV (MYL)

38.88
0.61 1.60
NASDAQ : Health Care
Prev Close 38.27
Open 38.46
Day Low/High 38.35 / 38.78
52 Wk Low/High 37.59 / 67.34
Volume 676.91K
Avg Volume 5.51M
Exchange NASDAQ
Shares Outstanding 535.98M
Market Cap 20.06B
EPS 1.80
P/E Ratio 37.05
Div & Yield N.A. (N.A)

Latest News

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.

Teva Pharmaceuticals Upgraded at Mizuho

Teva Pharmaceuticals Upgraded at Mizuho

Positive subscription trends and less downside risk this year have the company well positioned, Mizuho says.

Opioid Marketing Under Bipartisan Investigation

Opioid Marketing Under Bipartisan Investigation

Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.

Mylan CEO Defends Company From Proxy Critics

Mylan CEO Defends Company From Proxy Critics

As a June 22 shareholder reckoning approaches, CEO Bresch insisted that ISS and other critics have mischaracterized the nature of the pay package of Mylan's chairman.

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

Activist Investors Have a Big Day; Goldman Wields a Heavy Hand in Tech -- ICYMI Monday

Activist Investors Have a Big Day; Goldman Wields a Heavy Hand in Tech -- ICYMI Monday

Jeff Immelt's decision to step down as GE's CEO comes after pressure from Nelson Peltz's Trian Fund Management.

Mylan Board of Directors Slammed Over Executive Pay Amid EpiPen Scandal

Mylan Board of Directors Slammed Over Executive Pay Amid EpiPen Scandal

The two major proxy advisory firms recommends that Mylan shareholders vote against directors at the EpiPen maker.

Mylan Just Can't Catch a Break

Mylan Just Can't Catch a Break

Monday was a wild start to the week.

The New #44 Most Shorted Nasdaq 100 Component: Mylan

The most recent short interest data has been released for the 05/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

ISS Urges Mylan Shareholders to Vote Against Incumbent Board

ISS Urges Mylan Shareholders to Vote Against Incumbent Board

ISS argued that Mylan must be held accountable for reputation damage over drug pricing issues and the chairman's pay package.

Bank Deregulation Would Deprive Small Investors of a Voice: NYC Official

Bank Deregulation Would Deprive Small Investors of a Voice: NYC Official

New York City official Michael Garland had some strong words for GOP efforts to limit shareholder proposals.

Campaign Targeting Mylan Enters Final Week

Campaign Targeting Mylan Enters Final Week

The drugmaker tries to convince investors to support retaining board members and company pay plan.

People Shouldn't Be Surprised by Mylan's Desperate Attempt to Distort the Facts, Says Official

People Shouldn't Be Surprised by Mylan's Desperate Attempt to Distort the Facts, Says Official

Shareholders will vote on a "Just vote no" campaign at Mylan's June 22 meeting.

Mylan May Have Actually Started Something Beneficial; Snap's Stock Structure in Focus - ICYMI

Mylan May Have Actually Started Something Beneficial; Snap's Stock Structure in Focus - ICYMI

WWDC was in focus, but other news in the tech world also caught our eye.

Expect More Regulation From Republicans in Washington

Expect More Regulation From Republicans in Washington

Despite the rhetoric out of Washington, corporate America should prep for more regulation, not less, according to one leading executive adviser.

Mylan to Meet Sen. Grassley on EpiPen Claims

Mylan to Meet Sen. Grassley on EpiPen Claims

Mylan's offer follows Grassley's release of a Medicaid investigator's report concluding EpiPen may have received $1.27 billion more from a rebate program than the company was entitled.

Taxpayers Overpaid $1.27 Billion for Mylan's EpiPen, Senator Grassley Says

Taxpayers Overpaid $1.27 Billion for Mylan's EpiPen, Senator Grassley Says

Grassley is said to be pushing for documents and answers explaining why EpiPen was misclassified under the Medicaid Drug Rebate Program.

Institutional Investors Look to Block Re-Election of Mylan Board Members

Institutional Investors Look to Block Re-Election of Mylan Board Members

Pension funds are weary of the compensation the company's executives have received.

Starbucks' Howard Schultz Reveals the Sight of Feared Activist Carl Icahn Causes Him to Look Away

Starbucks' Howard Schultz Reveals the Sight of Feared Activist Carl Icahn Causes Him to Look Away

Schultz said Starbucks has been fortunate never to have attracted an activist investor.

Theravance Biopharma And Mylan Report Additional Phase 3 Data For Revefenacin (TD-4208) In Several Presentations At 2017 ATS

Presentations Review Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies; Report Prevalence of COPD Patients with Low Peak Inspiratory Flow Rate in Ongoing 12-Month Phase 3 Safety Trial

Theravance Biopharma And Mylan Report Additional Phase 3 Data For Revefenacin (TD-4208) In Several Presentations At 2017 ATS

Presentations Review Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies; Report Prevalence of COPD Patients with Low Peak Inspiratory Flow Rate in Ongoing 12-Month Phase 3 Safety Trial

Stocks Lift Off on Boeing, Lockheed Martin Deals; Crude Settles at One-Month High

Stocks Lift Off on Boeing, Lockheed Martin Deals; Crude Settles at One-Month High

Donald Trump gives Wall Street a burst of relief on Monday after causing worry on markets for the previous two weeks.

Defense Stocks Lift Wall Street, Qualcomm and Apple Lead Tech Shares

Defense Stocks Lift Wall Street, Qualcomm and Apple Lead Tech Shares

Defense stocks lift Wall Street to begin the week after Donald Trump's first leg of a trip abroad results in billions of dollars' worth of deals.

Midday Report: Boeing Leads the Dow; JPMorgan Has Faith in Qualcomm

Midday Report: Boeing Leads the Dow; JPMorgan Has Faith in Qualcomm

Defense stocks lifted Wall Street to begin the week after Donald Trump's first leg of a trip abroad resulted in billions of dollars' worth of deals.

Mylan Stock Gains Following Barclays Upgrade

Mylan Stock Gains Following Barclays Upgrade

The firm upgraded Mylan to 'overweight' from 'equal weight.'